Young Jonathan 4

4 · Akero Therapeutics, Inc. · Filed Nov 26, 2025

Form 4

Period: 2025-11-24

Chief Operating Officer

Transactions

Exercise/Conversion
Common Stock
2025-11-24$21.09/sh+4,284$90,350→ 201,182 total
Exercise/Conversion
Common Stock
2025-11-24$28.35/sh+3,527$99,990→ 204,709 total
Exercise/Conversion
Common Stock
2025-11-24$21.10/sh+4,739$99,993→ 209,448 total
Gift
Common Stock
2025-11-26−9,259→ 200,189 total
Exercise/Conversion
Stock Option (Right to Buy)
2025-11-24−4,284→ 0 total
Exercise: $21.09Exp: 2029-12-12→ Common Stock (4,284 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2025-11-24−3,527→ 0 total
Exercise: $28.35Exp: 2030-12-07→ Common Stock (3,527 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2025-11-24−4,739→ 0 total
Exercise: $21.10Exp: 2031-12-07→ Common Stock (4,739 underlying)

Holdings

Footnotes (3)

[F1]These shares are held in irrevocable trusts for the benefit of the Reporting Person's children. The Reporting Person's spouse is trustee of the trusts. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
[F2]Represents shares of the Issuer's Common Stock that the reporting person donated as a gift to a donor advised fund.
[F3]The options are vested and currently exercisable.

Documents

1 file